drugset / Trial / NCT03218241

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

NCT03218241

Phase 1 Completed 32 enrolled Portola Pharmaceuticals
RandomizedSingle-groupDouble-blindOther

Summary

This is a single center, double-blind, randomized, placebo-controlled, ascending, single dose study of PRT064445 or its matching placebo, in healthy subjects.

Timeline

Start
2012-06
Primary completion
2012-09
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Andexanet alfa Protein / enzyme biologic Intravenous

Indications

No indication recorded.